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The vast array of G-protein-coupled receptors (GPCRs) play crucial roles in both
physiological and pathological processes, including vision, coagulation, inflammation,
autophagy, and cell proliferation. GPCRs also affect processes that augment cell
proliferation and metastases in many cancers including melanoma. Melanoma is the
deadliest form of skin cancer, yet limited therapeutic modalities are available to patients
with metastatic melanoma. Studies have found that both chemokine receptors and
protease-activated receptors, both of which are GPCRs, are central to the metastatic
melanoma phenotype and may serve as potential targets in novel therapies against
melanoma and other cancers.
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G-PROTEIN-COUPLED RECEPTORS
The discovery of the 7-pass transmembrane G-protein-coupled receptors (GPCRs) has proven
vastly beneficial in the development of modern medicines as nearly half of all drugs today act on
GPCRs (Tautermann, 2014). More than 850 GPCRs are found in the human body and function
as key mediators in signal transduction pathways from the cell exterior (Tautermann, 2014; Liu
et al., 2016). Through specific interactions between the GPCR and the heterotrimeric G-protein
molecular switches (G-alpha, G-beta, G-gamma), numerous intracellular signaling pathways are
modulated, affecting various physiological processes including vision (Palczewski et al., 2000),
blood clotting (Huang et al., 2007), cellular proliferation (Yu and Brown, 2015), and autophagy
(Wauson et al., 2014) among others (Figure 1).
GPCRs also have specific roles in human disease, which make them excellent targets in drug
development. For example, neural pathways that would produce symptoms of schizophrenia are
disrupted by the antipsychotic mediators Clozapine and Risperidone, which block specific GPCRs
that normally bind to serotonin (Fribourg et al., 2011). Deregulation of Beta-adrenergic receptors,
a type of GPCR, is commonly found in various cardiomyopathies (Kamal et al., 2012). Moreover,
GPCRs have also been named as key regulators of tumor progression and metastasis through
various intracellular pathways deregulated in cancers, including MAPK and PI3K/AKT pathways
(Dorsam and Gutkind, 2007).
The wide range of functions affected by GPCRs, including GPCR’s ability to bind a variety of
ligands, such as peptides, antibodies, and small molecules, has resulted in the extensive utilization
of agonists, antagonists, and inverse agonists (Richard et al., 2001; Feigin, 2013).
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FIGURE 1 | Effects of protease activated receptor and chemokine receptor activation on several signaling pathways involved in melanoma
metastasis. Abbreviations: MAPK, mitogen-activated protein kinase; PI3K, phosphoinositide 3 kinase; JAK, Janus kinase; PLC, phospholipase C; PIP2,
phosphatidylinositol-bisphosphate; IP3, inositol triphosphate; DAG, diacylglycerol; PKC, protein kinase C; Cx-43, connexin-43; MMP, matrix metalloproteinase;
VEGF, vascular endothelial growth factor; Ang-2, angiopoietin-2; CXCL1, CXC chemokine motif ligand 1.
GPCRs AND CANCER
Young et al. (1986) discovered and characterized a novel
oncogene that encoded a GPCR, which they named mas.
These were the first experiments demonstrating the GPCR’s
transformative activity in tumorigenesis. Since then, many
GPCRs have been identified as being involved not only in
tumorigenesis but also in metastasis and angiogenesis. In fact,
many tumors rely heavily on GPCRs for these other processes,
including the protease-activated receptor (PAR), prostaglandin
receptors, sphingosine receptors, and the CXCR2 and CXCR4
chemokine receptors (Richard et al., 2001).
Mutations affecting GPCRs can cause abnormal increases
in receptor expression and activity that can ultimately lead
to the development of cancer. The range of mutations from
GPCRs can affect basal activity, ligand binding, GPCR-G protein
interaction, cell surface expression, GPCR signaling, and disease
(Stoy and Gurevich, 2015). Recently, GPCR mutations, copy
number alterations, differential gene expression, and methylation
changes have been discovered by genomic analyses in a variety
of cancers (Feigin, 2013). This information could potentially lead
to the utilization of GPCR-targeted therapeutics in patients with
GPCR-driven tumors.
Moreover, various cell types stimulate cell proliferation
by potent mitogens such as thrombin, lysophosphatidic acid,
gastrin-releasing peptide, endothelin, and prostaglandins, acting
on their cognate GPCR. Studies have even shown that wild-type
GPCRs have the capability to become tumorigenic upon exposure
to an excess of locally produced or circulating ligands and agonist
(Julius et al., 1989; Gutkind et al., 1991). Additionally, mutations
in key conserved residues can render the GPCRs constitutively
active independent of the presence of their ligands (Allen et al.,
1991; Pollock et al., 2003).
Although GPCRs are involved in many cancer types, herein,
we will discuss the involvement of several GPCRs known to
contribute to tumor growth and metastasis of human melanoma.
Although melanoma is the fifth most common cancer type
in men and seventh in women, it is the deadliest form of
skin cancer (Siegel et al., 2016). Even with the discovery of
several immunotherapeutic drugs that have had positive effects
on patient survival rates, the number of drugs available for
advanced metastatic disease remains limited. Thus, GPCRs seem
to offer another potential therapeutic modality for the treatment
of melanoma (Valko-Rokytovska et al., 2016). Moreover, there is
evidence that GPCRs are involved in resistance to RAF and MEK
inhibitors in melanoma harboring a common mutation in BRAF
(V600E; Johannessen et al., 2013). As such, targeting GPCRs may
be important not only for preventing melanoma progression but
also in treating drug-resistant melanoma.
GPCRs and Melanoma
GPCRs are involved in tumorigenesis and metastatic
progression of melanoma in all stages, including transformation,
proliferation, migration, invasion, and angiogenesis (Li et al.,
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2005; Lee et al., 2008). In several human cancers, including
non-small cell lung cancer, breast cancer, prostate cancer,
gastric cancer, and melanoma, the most implicated GPCRs are
endothelin receptors, chemokine receptors, and lysophosphatidic
acid receptors. Not only are GPCRs up-regulated in primary
tumors but they have also been found in metastatic cancer cells.
Further analysis of cancer samples in different disease stages
showed that some GPCRs, such as endothelin receptor A, may
be involved in early tumor progression while other GPCRs,
such as CXCR4, are critical for tumor invasion and metastasis
(Li et al., 2005). Melanoma studies have revealed a myriad of
GPCR and mutations found in GPCRs that may be involved in
melanoma progression including, melanocortin type 1 receptor,
endothelin receptor, metabotropic glutamate receptor-1, 3, and
8, platelet-activating factor receptor, and Wnt/frizzled receptor
among others (Lee et al., 2008; Prickett et al., 2011). In this
review, we will concentrate on two families of GPCR that
have been identified as being crucial for the progression and
metastasis of melanoma: chemokine receptor family and PAR
family members.
Chemokine Receptors
Chemokines are small polypeptide signaling molecules that bind
to and activate the G-protein-coupled chemokine receptor. They
have the unique ability to induce chemotaxis of leukocytes,
but can produce a wide range of cellular signals that affect
cell proliferation and promotion of angiogenesis (Payne and
Cornelius, 2002).
Chemokine receptors have been found to be involved in
cancer progression in various cancers, including melanoma.
Various studies looking at signaling pathways in metastatic
melanoma suggest that the expression of chemokine receptors
and chemokines may grant melanoma cells the ability to inhibit
an immune response and alter the tumor microenvironment to
stimulate angiogenesis (Lee et al., 2008). Studies on melanoma
cell adhesion, survival, and chemo attraction have further
elucidated chemokines’ particular role in directing site-specific
metastasis. Different metastatic sites express a gradient of varying
chemokines. As such, melanoma cells expressing a particular
chemokine receptor will preferentially metastasize to sites based
upon receptor detection of the chemokine gradient elaborated by
a specific organ or tissue microenvironment (Pinto et al., 2014;
Valko-Rokytovska et al., 2016). For example, CCR7, CCR10, and
CXCR3 have been associated with a greater risk of lymph node
metastasis while CXCR4 has been associated with pulmonary
metastasis (Pinto et al., 2014). Studies have also shown that
CXCL8, CXCR1, and CXCR2 have been associated with tumor
progression in melanoma by means of affecting the growth of the
tumor cells, angiogenesis, and metastasis (Bar-Eli, 1999).
Protease-Activated Receptors
Unlike typical ligand-binding interactions that occur with other
types of GPCRs, PAR activation occurs through proteolytic
cleavage of the N-terminal domain of the receptor by serine
proteases. This cleavage causes an irreversible conformational
change in the receptor creating a new amino terminus that acts
as a tethered ligand to activate the receptor (Vu et al., 1991). Four
members of the PAR family have been identified (PAR-1, -2, -3,
and -4). These PARs differ in the specific proteases that activate
them and their localization.
PAR-1
The first PAR to be identified was the thrombin receptor PAR-1
(Vu et al., 1991). It is expressed on a wide variety of cell types,
such as platelets, endothelial cells, fibroblasts, neurons, astrocytes,
T-cells and smooth muscle cells, among others (Macfarlane et al.,
2001). Furthermore, PAR-1 has been found to be expressed by a
wide range of cancer cells, including, but not limited to, breast,
colon, prostate, and melanoma. Upon activation, the PAR family
stimulates multiple intracellular signaling pathways including the
MAPK and PI3K pathways that affect crucial cellular processes
including cell proliferation and survival, thereby making PAR
activation one of the essential components of functioning cells. As
such, PAR-1 has significant roles not only in coagulation, wound
healing and inflammation, but also in the progression of several
cancer types (Jin et al., 2016).
In melanoma, the development of tumor cells is directly
dependent on the interaction between the cells and the inhabited
microenvironment. A key player in this communication is
the thrombin receptor (PAR-1; Tellez et al., 2003). Thrombin
activation precedes a coagulation deluge that leads to cell
proliferation, cell adhesion, angiogenesis, and invasion, which
ultimately promotes tumor growth and metastasis (Villares et al.,
2008; Zigler et al., 2011). In vivo targeting of human PAR-1
with the use of siRNA-encapsulated liposomes showed a decrease
in melanoma growth and experimental metastasis, as well as a
decrease in the expression of several angiogenic and metastatic
genes, including vascular endothelial growth factor (VEGF),
interleukin 8 (IL-8), and matrix-metalloprotease 2 (MMP-2;
Villares et al., 2008). Similar findings have not only been seen
in in vivo and in vitro studies, but also in patient samples using
tissue microarrays (TMA). Quantitative analysis of a melanocytic
microarray showed a significant increase in PAR-1 in metastatic
melanoma samples and primary melanoma as compared to
dysplastic nevi (Tellez et al., 2007).
Further studies in our lab elucidating the role of PAR-1 in
melanoma growth and metastasis found that PAR-1 affects
Maspin and Connexin-43, two other genes involved in cancer
cell growth and metastasis. Maspin is a tumor-suppressor
gene found in melanoma and other cancers such as breast
cancers. It was found that increased PAR-1 expression and
activity found in metastatic melanoma cells, negatively
regulates Maspin expression and promotes the metastatic
melanoma phenotype as evidenced in vivo when Maspin
was overexpressed in PAR-1 silenced cells (Villares et al.,
2011). Concomitantly, PAR-1 was found to increase the
tumor promoting-function of Connexin-43, a gap junction
intracellular communication (GJIC) protein that was found to
increase melanoma cell attachment to endothelial cells, thereby
augmenting the metastatic phenotype in melanoma (Villares
et al., 2009).
These studies on melanoma, as well as other studies on
pancreatic cancer and PAR-1 (Queiroz et al., 2014), demonstrate
a potential therapeutic benefit in targeting PAR-1. Interestingly,
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25 years after the first PAR discovery, an antagonist targeting
this receptor was approved in 2014 for human use (Vorapaxar)
for the prevention of thrombotic cardiovascular events (French
and Hamilton, 2016). Whether this drug can help patients with
melanoma metastasis is yet to be determined.
PAR-2
Although there is a high degree of homology to PAR-1, PAR-
2 is not activated by thrombin, but mostly by trypsin and
other trypsin-like proteases, such as tryptase and factor Xa
(O’Brien et al., 2001; Bahou, 2003). The tethered ligand domain
of cleaved PAR-1 has been found to transactivate the PAR-2
receptor when both are present in close physical proximity to
one another (O’Brien et al., 2000). Thus, cross-activation of
PAR-2 by PAR-1 could facilitate PAR-1s effect on melanoma
metastasis.
The effect of PAR-2 on tumor progression is thought to be
due to an increase in chemotaxis mediated by the high levels
of calcium released by PAR-2-activated cells (Yau et al., 2016).
Moreover, activated PAR-2 results in increased inflammatory
conditions via activation of the NFkB pathway with concomitant
decrease of anti-inflammatory, tumor-suppressor microRNAs,
including let-7d, miR-23b, and miR-200c (Johnson et al., 2016).
As inflammation is a risk factor for tumorigenesis, activation of
PAR-2 can regulate proliferation, angiogenesis, and metastasis
(Johnson et al., 2016).
PAR-3 and PAR-4
Both PAR-1 and PAR-3 are thrombin receptors. Studies
have shown that PAR-3 mediates the effect of thrombin to
produce the cell-adhesion molecule VCAM-1 and cytokine
production in endothelial cells as well as cell proliferation
of malignant B cells (Kalashnyk et al., 2013). However,
studies have found that activated PAR-3 does not result in
signaling through G-proteins when PAR-4 is not present
(Nakanishi-Matsui et al., 2000). PAR-4 directly plays a role
in platelet activation by thrombin as it is required for
platelet pro-coagulant functions during thrombus formation
(French and Hamilton, 2016). The pro-coagulant environment
of circulating tumor cells supports metastases. As such,
therapeutics targeting some of the molecules of blood
coagulation activation, such as coagulation proteases and PARs,
could positively affect patient survival (Lima and Monteiro,
2013).
GPCRs AS THERAPEUTIC TARGETS IN
CANCER
The ubiquitous nature of GPCRs in regulating multiple essential
cell functions and diseases has resulted in more than 50% of
drugs today targeting GPCRs including chemokine receptors
and PARs. For example, the use of the chemokine receptor
antagonist Maraviroc is an effective HIV antiviral drug that
blocks the chemokine CCR5 which is essential for HIV
entry into host cells (Dorr et al., 2005; Fatkenheuer et al.,
2005). Vorapaxar and Atopaxar are PAR-1 antagonists used
in patients with thromboembolism that reduce the risk of
cardiovascular death and myocardial infarcts (Capodanno et al.,
2012).
Despite the promising results from many GPCR-targeting
drugs in various diseases, the development of cancer therapeutics
targeting GPCRs has only started to become more mainstream
within the last 5 years. There are currently several clinical
trials that are testing GPCR-targeting drugs for different types
of cancer. Vantictumab, a monoclonal antibody that targets
the GPCR Frizzled, an essential protein in Wnt signaling, is
in several phase I clinical trials: Vantictumab plus docetaxel
for recurrent non-small-cell lung cancer; Vantictumab plus
Paclitaxel and Gemcitabine for stage IV pancreatic cancer
and Vantictumab plus Paclitaxel for recurrent and metastatic
breast cancer. Other clinical trials include the use of the
non-steroidal anti-inflammatory drug (NSAID) Sulindac in
combination with anti-VEGF antibody (Bevacizumab) and anti-
EGFR inhibitor (Erlotinib) for the treatment of squamous
cell carcinoma of the head and neck. A new clinical trial
is recruiting patients with colon cancer to determine the
expression of cannabinoid receptor, a GPCR, as compared
to patients with inflammatory bowel conditions. Most of
these studies are ongoing or have just been completed
and the results from these trials will shed light on the
effectiveness of targeting these GPCRs as possible cancer
therapies.
CONCLUSION
Although tumor progression and metastasis is a multi-
factorial process, one of the key players in these cancer
processes is the GPCR. In melanoma and other cancers,
GPCRs, including chemokine receptors and protease-activated
receptors, are crucial in favoring a more pro-metastatic
phenotype. Chemokines and their respective GPCR receptors
promote angiogenesis and organ-directed metastases, while
PAR activation induces a more inflammatory, pro-coagulant
environment and controls key cell signaling pathways involved
in melanoma growth and metastasis. Given the experimental
data obtained in recent years on the effects of GPCRs in
cancer, the potential in developing therapeutics to combat them
has increased exponentially and could lead to better patient
outcomes.
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